

For Public Release

NZX Limited
Wellington

7 June 2024

Cannasouth Announces Outcome of Watershed Meeting for Cannasouth Bioscience Limited

Cannasouth Limited (NZX:CBD) announces that a watershed meeting for its wholly owned subsidiary, Cannasouth Bioscience Limited, was held on Thursday, 6 June 2024.

At the watershed meeting, the creditors of Cannasouth Bioscience Limited resolved to hand the control of the company back to its directors. Subsequently, Cannasouth Limited (as sole shareholder) resolved to place the company into liquidation.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Garry Whimp

Administrator, Blacklock Rose Ltd
Email: gwhimp@blr.co.nz
Mobile: 021 587 230

Ben Francis

Administrator, Blacklock Rose Ltd
Email: bfrancis@blr.co.nz
Mobile: 021 042 6991

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Equis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>